ADC Specialist Sinks on Safety Concerns: What Pharma Teams Need to Know

Key Takeaways

• ADC Therapeutics’ June 3, 2026 8-K said LOTIS-5 met PFS (HR 0.73; p=0.008) with median PFS 6.1 vs 4.7 months versus R-GemOx.
• ORR was 58.1% vs 45.2% and CR 39.5% vs 26.7%; OS HR was 0.96 with no detrimental OS effect claimed in the disclosure.
• Grade 5 TEAEs were higher in the Zynlonta arm (27 patients / 13.2% vs 9 / 4.6% in control), mostly in patients aged 75 or older per company materials.
• A PR Newswire investor notice cited roughly a 66.5% two-session share drop after the safety-efficacy mix became public.

What did the LOTIS-5 topline show?

Per the company’s June 3, 2026 Form 8-K, LOTIS-5 compared ZYNLONTA (loncastuximab tesirine-lpyl) plus rituximab versus R-GemOx in relapsed/refractory DLBCL after one or more prior systemic therapies.

Primary endpoint PFS by independent review met statistical significance (HR 0.73; two-sided p=0.008). Secondary efficacy included ORR 58.1% vs 45.2%, CR 39.5% vs 26.7%, median DOR 9.2 vs 7.7 months, and median duration of CR 16.8 vs 12.3 months.

Why did safety overshadow the PFS win?

The accompanying exhibit states overall TEAE rates were broadly similar, but serious AEs, withdrawals, and Grade 5 events were higher on the Zynlonta arm. Company detail highlighted 27 Grade 5 TEAEs (13.2%) versus 9 (4.6%) on control, with most test-arm Grade 5 events in patients ≥75 years. See the SEC Exhibit 99.1 topline release.

PR Newswire coverage of subsequent investor litigation notices also restated the 27 vs 9 death counts and a ~66.5% two-day share decline to $1.03 on June 5, 2026.

Key numbers for BD and medical diligence

• PFS HR 0.73; median 6.1 vs 4.7 months
• OS HR 0.96 (company: no detrimental OS effect; notes treatment switching in control)
• CR rate absolute difference about 12.8 percentage points
• Grade 5 TEAE rate gap about 8.6 percentage points
• Company later pointed to a pre-sBLA FDA meeting targeted for August 2026

What remains unproven for regulators and payers?

A confirmatory PFS win does not automatically equal a clean benefit-risk narrative in older adults. Label negotiations may focus on age-based risk management, infection monitoring, and whether combination use with rituximab changes the monotherapy risk profile already known for Zynlonta.

Do not invent infection percentages beyond the Grade 5 and SAE qualitative statements in the 8-K until full tables appear in a medical-meeting dataset.

How should ADC deal models change?

Re-underwrite peak sales with a safety haircut for age ≥75 segments, raise probability of regulatory delay, and track the August 2026 pre-sBLA meeting outcome. Competitive ADC diligence should now ask explicitly for Grade 5 rates by age band in every Phase 3 package.

Competitive read-through for other lymphoma ADCs

Rival ADC developers should expect questions about Grade 5 rates by age band in every late-stage package. A PFS win with a wide fatal-AE gap can still stall label expansion or force narrow populations.

Hospital formulary committees will weigh the 1.4-month median PFS gain against infection and fatal-event differentials, especially for patients aged 75 and older. That debate will shape uptake even if FDA ultimately allows an sBLA path.

For BD, revisit any Zynlonta combination collaboration terms that assumed a clean confirmatory narrative. Add termination or renegotiation triggers tied to Grade 5 imbalances and FDA meeting minutes once available.

Related NovaPharma coverage

• ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution
• FDA Delays AstraZeneca Camizestrant Decision
• Grail Galleri Trial Missed Primary Endpoint

Frequently Asked Questions

Primary Sources

1. SEC 8-K — ADC Therapeutics LOTIS-5 topline disclosure
2. SEC Exhibit 99.1 — LOTIS-5 press release text
3. PR Newswire — investor notice summarizing deaths and share move